Beximco Pharmaceuticals Ltd

Beximco Pharmaceuticals Ltd (Beximco Pharma) belongs to the largest business conglomerate in Bangladesh, the BEXIMCO group. Beximco Pharma is engaged in manufacturing both finished formulations and active pharmaceutical ingredients (APIs). The company was incorporated in 1976 and commenced operations in 1980 with the manufacturing and marketing of products of Bayer AG, Germany and Upjohn Inc., USA under licensing arrangements. In 1983, the company started manufacturing its own formulations and it launched export operation in 1992. In 2002 Beximco Infusions Ltd, the company that produces intravenous fluids was amalgamated with the parent company. Today Beximco Pharma is the largest exporter of pharmaceuticals in the country and the only company to win National Export Trophy (Gold), the highest national accolade for export, for record three times. Company’s state-of-the-art manufacturing facilities are certified by major regulatory bodies. As a public limited company, its shares are actively traded in Dhaka Stock Exchange and Chittagong Stock Exchange, and Beximco Pharma is the only company in the country which got listed on AIM of London Stock Exchange.

Business Operations
The company produces formulations of key therapeutic areas which include anti-infectives, gastro-intestinal, cardio-vascular, anti-diabetic, NSAIDs, respiratory, CNS etc, and its products are available in almost all types of dosage forms, eg., tablet, capsule, syrup,  suppositories, ointments, eye drops, injectables, metered dose inhalers etc. In the domestic market Beximco Pharma ranks 2nd among 230 companies. In 2009 the company achieved annual sales turnover of BDT 5000 million with growth of 21%. The company produces more than 100 branded generics which are available in various dosage forms and many of them are leaders in their respective therapeutic categories, notable among them are Napa, Neoceptin R, Neofloxin, Atova, Amdocal, Bextrum and Azmasol.  Being the largest exporter of pharmaceuticals in the country, the company has growing presence in more than 80 countries across Africa, Latin America, Asia, Middle East and Central America. The company now plans to enter the regulated markets with its generic portfolio and aims to achieve export sales of more than $100 million by the year 2014.                                                                       
Beximco Pharma’s API portfolio includes paracetamol, amoxicillin, ampicillin, and the company has taken up major expansion program to produce cephalosporins, ranitidine, omeprazole and ciprofloxacin.
Manufacturing Capabilities
Located at Tongi, near the capital city Dhaka, BPL’s manufacturing site is spread over an area of 20 acres which houses a number of self contained production units including oral solids, metered dose inhalers, intravenous fluids, liquids, ointments, creams, suppositories, ophthalmic drops, injectables, nebulizer solutions etc.  Beximco Pharma’s modern manufacturing facilities have been audited and approved by major regulatory authorities like TGA (Australia), GCC (Gulf) and ANVISA (Brazil), among others.  Its state-of-the art metered dose inhaler unit is also qualified by Asthma Drug Facility (ADF) France, UNICEF and Global GlaxoSmithKline.

The new oral solid dosage facility, designed and built according to the guidelines of USFDA, consists of five lines with an installed annual capacity to produce 5 billion tablets on a single shift. The plant and machinery throughout the site have been sourced mostly from renowned European companies.

Beximco Pharma is among the very few companies in the world who proactively converted CFC based formulations to ozone friendly HFA Inhalers in compliance with the Montreal Protocol. The company is now the single largest producer of MDIs in Bangladesh, and the only company in Asia to contract manufacture GSK’s Ventolin inhaler. The MDI facility has been designed and installed with the technical collaboration from Pamasol, having an annual production capacity of 15 million canisters which will increase upto 30 million soon.

The bulk drug unit of Beximco Pharma for producing paracetamol is also located at Tongi, while penicillin API and formulation units are situated at Kaliakoir, a few kms from the main site. 

Contract Manufacturing Opportunities
With decades of experience in generic drug manufacturing, world class facilities as well as with its significant cost advantages, Beximco Pharma can be an ideal partner for you to meet your contract manufacturing needs.  Since its inception, Beximco Pharma has established itself as a reliable partner for a number of global MNCs. These partnerships have provided BPL much valuable expertise and know-how to manufacture world-class products. The company has maintained a track record of sound professionalism and its management has always adhered to international standards.  Currently the company has contract manufacturing agreement with GlaxoSmithKline for producing Metered Dose Inhaler product. The company offers significant cost advantage as a manufacturer, as the average wage in Bangladesh is among the lowest in the world, and at least two to three times lower than that in China or India. Prospective partners can benefit themselves with competitive advantages like availability of highly skilled manpower at a very low cost, low energy cost, Govt. policy support, WTO waiver, investor friendly environment etc.

Corporate Social Responsibility
Commitment to our society is an integral part of the way we are doing business. Each year, a substantial amount of our earning is ploughed back into social causes, so that our society gets benefited while we continue to grow.   We donate and make available a large quantity of medicines to the victims of natural disasters, both national and international. Medicines for the victims of earthquake in Pakistan, tsunami in Sri Lanka, and cyclone SIDR in Bangladesh are a few worth mentioning. Since 2005, Beximco Pharma has been supplying ARV drugs through a leading local bank, for treating the AIDS patients in Bangladesh. These ARV drugs are distributed through NGOs working for the HIV/AIDS patients. Responding to the pandemic Avian as well as recent Swine Flu, BPL donated large quantities of oseltamivir capsue, Oseflu, to the govt. of Bangladesh as well as different reputed organizations including ICDDR,B. Oseflu was also supplied to the government of Myanmar as a part of our CSR initiatives.

Future Plans and Initiatives
BPL is taking aggressive expansion program to cater to the growing demand from domestic as well as overseas markets. The company is finding opportunities in newer territories, particularly in regulated markets. The company has made significant investment in building capabilities, both infrastructure and its people, to capitalize on the generic drug opportunities in the developed markets like EU and US. With major expansion in capacity and significant expertise in inhaler formulations, BPL aspires to become a global player in MDIs within the next 3-4 years. It has also taken up projects to diversify into vaccines, biopharma and neutraceuticals while it continues to explore innovative drug delivery systems to enrich its product portfolio with transdermal patches, oral thin film, DPI etc. Besides, the company is always keen to improve on its reverse engineering capabilities in formulation development and to further strengthen the API capabilities to become more competitive in global marketplace. Generic drug capabilities, competitive cost advantages, and the manufacturing platform, benchmarked to global standards, have rendered the company ideally positioned to meet the contract manufacturing needs for producing affordable generics.